GLAXOSMITHKLINE ORD GBP0.25

Symbol: GSK

Whilst we endeavour to price investments on a real-time streaming or 15 min delayed basis, some prices may be as at close of business from the previous working day.

Invest in this share within an ISA, JISA, SIPP or Investment Account

Overview

Core Data
Latest Dividend Information

Ex-Dividend Date 12 Nov 2020
Pay Date 14 Jan 2021
Total Dividends - Year to Date80
Dividend Yield (%)5.7414

Historical Data & Ratios

Avg Volume Over 10 Days6.7225
Market Cap (M)69041.5500
Price/Earnings (PE)10.8664
Earnings Per Share128.23
Revenue Per Share6.7293
Return on Equity %58.9280

1 Month Performance Chart

One Month Chart

Broker View
Data shown is based on the past 75 days of broker views.

ActionBrokers

Strong Buy10

Buy1

Neutral11

Sell0

Strong Sell1

Brokers 10 1 11 0 1
Consensus

ConsensusBuy

Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.

Cost and Charges Information

This calculator provides you with costs and charges information regarding our charges and, where relevant, the costs within this investment product

Account Type

  • Investment Account
  • Stocks & Shares ISA
  • SIPP

Annual charges

These are the annual costs based on an initial investment amount of over 1 year assuming a net zero growth rate

Cost Category % of Investment lump sum costs
Our annual fee

Our annual fee

Includes our platform fee at 0.35% per annum for Funds (up to £250,000) and Stocks & Shares (min £24 max £240), plus SIPP administration fee (if applicable, only charged if <£30,000 held) - see here
0.35%
Dealing charges

Dealing charges

Any one-off commission charges associated with investing. Note that government taxes and levies are not included
N/A
Product provider costs

Product provider costs

Product provider costs shown are inclusive of the fund ongoing charges figure (OCF), transaction costs and incidental costs
N/A N/A
Total (£)

Total (£)

Costs per annum displayed in monetary value
Total (%)

Total (%)

Costs per annum displayed as a percentage of investment value

Cumulative effect of charges on your investment's return

This illustration assumes that costs occur evenly throughout the year, charges are paid out of the investment evenly throughout the year, and that an annual growth rate of applies evenly throughout the year, before any charges including product charges

lump sum invested with an assumed growth rate of 1 year years
What you might get back at  with no charges applied

What you might get back at  with no charges applied

These are the illustrative values of a  investment after growth and no costs applied at the end of the defined period
Annual charges

Annual charges

These are the annual costs based on an initial investment amount of assuming a net zero growth rate
Effect of charges on return (%)

Effect of charges on return (%)

These are the overall costs in percentage terms, based on an initial investment amount of assuming a growth rate
Effect of charges on return (£)

Effect of charges on return (£)

These are the overall costs in monetary value, based on an initial investment amount of assuming a growth rate
What you might get back at with charges applied

What you might get back at with charges applied

These are the illustrative values of a investment after growth and costs at the end of the defined period

This illustration is not a forecast of future investment performance but merely a means to demonstrate the potential impact of costs and charges for an assumed return of . Whilst we make reasonable endeavours to ensure the accuracy of third party charges information, this is intended for illustrative purposes only and should not be relied upon. We do not warrant or represent that this information is accurate, complete or up to date, therefore we accept no responsibility or liability for its use

Charts

  • Chart Options

    Select Timeframe Add a sector as a comparator Add an index as a comparator Add a share as a comparator

      Add a moving average as a comparator Add a lower indicator as a comparator Chart Style Current Comparators

      Company

      Business Summary

      GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

      Financial Summary

      BRIEF: For the nine months ended 30 September 2020,GlaxoSmithKline plc revenues increased 2% to £25.36B. Netincome increased 52% to £5.07B. Revenues reflect ConsumerHealthcare segment increase of 19% to £7.67B, US segmentincrease of 5% to £10.67B, Europe segment increase of lessthan 1% to £6.07B. Net income benefited from Unallocatedsegment loss decrease of 80% to £462M, Consumer Healthcaresegment income increase of 27% to £1.83B.

      Financials


      Income Statement - All values are in GBP (M).

      Year Ending

      31/12/2019

      31/12/2018

      31/12/2017

      31/12/2016

      31/12/2015

      31/12/2014

      Total Revenue 33,754.00 30,821.00 30,186.00 27,889.00 23,923.00 23,006.00
      Gross profit 23,586.00 21,249.00 20,869.00 18,991.00 15,881.00 15,968.00
      Operating Profit/Loss 6,961.00 5,486.00 4,181.00 2,598.00 11,165.00 3,597.00
      Profit Before Tax 6,221.00 4,800.00 3,525.00 1,939.00 10,526.00 2,968.00
      Profit After Tax 5,268.00 3,921.00 3,247.00 1,062.00 8,372.00 2,831.00
      Equity Holders of Parent Company 4,645.00 3,623.00 1,532.00 912.00 8,422.00 2,756.00
      Minority Interest 6,329.00 -1,111.00 2,920.00 3,689.00 3,814.00 598.00


      Balance Sheet - All values are in GBP (M).

      Year Ending

      31/12/2019

      31/12/2018

      31/12/2017

      31/12/2016

      31/12/2015

      31/12/2014

      Total Non-Current Assets 60,201.00 41,139.00 40,474.00 42,370.00 36,859.00 25,973.00
      Total Current Assets 19,491.00 16,927.00 15,907.00 16,711.00 16,587.00 14,678.00
      Total Assets 79,692.00 58,066.00 56,381.00 59,081.00 53,446.00 40,651.00
      Total Liabilities 61,335.00 54,394.00 52,892.00 54,118.00 44,568.00 35,715.00
      Total Net Assets 18,357.00 3,672.00 3,489.00 4,963.00 8,878.00 4,936.00
      Shareholders Funds 11,405.00 4,360.00 -68.00 1,124.00 5,114.00 4,263.00
      Minority Interests 6,329.00 -1,111.00 2,920.00 3,689.00 3,814.00 598.00
      Total Equity 18,357.00 3,672.00 3,489.00 4,963.00 8,878.00 4,936.00

      Outlook

      Broker View
      Data shown is based on the past 75 days of broker views.

      ActionBrokers

      Strong Buy10

      Buy1

      Neutral11

      Sell0

      Strong Sell1

      Brokers 10 1 11 0 1
      Consensus

      ConsensusBuy

      Not advice based on your circumstances. Does not constitute a recommendation to buy or sell this or any other security. Selected data supplied by Digital Look® Read more.

      Forecasts

      Year 2020 2021 2022
      Revenue £34,211.90mn £35,326.70mn £36,888.40mn
      Pre-tax-Profit £8,222.75mn £8,438.59mn £9,012.37mn
      EPS £1.16p £1.15p £1.23p
      EPS Growth -6.32% -1.07% 7.51%
      P/E 12.02 12.15 11.3
      PEG Ratio -1.90 -11.33 1.50
      Dividend 80.00p 80.00p 79.70p
      Yield 5.68% 5.68% 5.66%

      Upgrades & Downgrades (Latest 10)

      DateBrokerRecommendationPriceOld TargetNew TargetChange
      2nd Nov 2020Liberum CapitalUpgrade1325p1840p1730pBuy
      29th Oct 2020Shore CapitalReiteration1304p0p0pSell
      15th Oct 2020Shore CapitalReiteration1376p0p0pSell

      Time & Sales

      All prices are in GBX and times are in GMT. Last 20 trades shown.

      Date Time Price Volume Type
      15 Jan 2021 14:28 1,405.8 151 Buy
      15 Jan 2021 14:28 1,405.8 255 Buy
      15 Jan 2021 14:28 1,405.8 27 Buy
      15 Jan 2021 14:27 1,405.6 400 Sell
      15 Jan 2021 14:27 1,405.8 3 Buy
      15 Jan 2021 14:27 1,405.6 250 Sell
      15 Jan 2021 14:27 1,405.6 76 Sell
      15 Jan 2021 14:27 1,405.6 150 Sell
      15 Jan 2021 14:27 1,405.6 10 Sell
      15 Jan 2021 14:27 1,405.6 316 Buy
      15 Jan 2021 14:27 1,405.6 315 Buy
      15 Jan 2021 14:27 1,405.6 1,883 Buy
      15 Jan 2021 14:27 1,406 172 Sell
      15 Jan 2021 14:27 1,406.2 486 Sell
      15 Jan 2021 14:27 1,406.2 239 Sell
      15 Jan 2021 14:27 1,406.2 540 Sell
      15 Jan 2021 14:27 1,406 459 Sell
      15 Jan 2021 14:27 1,406 165 Sell
      15 Jan 2021 14:27 1,406 42 Sell
      15 Jan 2021 14:27 1,406.2056 402 Buy

      Selected data supplied by Thomson Reuters ©  View restrictions.

      VIEW ALL MARKET NEWS

      Investment involves risk. You may get back less than invested.